Cana­di­an cell ther­a­py biotech Ser­no­va said Sun­day that its board chair­man Ross Haghigh­at has re­signed af­ter be­ing in­dict­ed by the De­part ...

Boundless Bio halts BBI-355 monotherapy & combinations due to toxicity, shifts to BBI-355/BBI-825 combo. Cuts 33% of staff to ...

The CDC will no longer recommend routine Covid-19 vaccines for kids and pregnant women after HHS Secretary Robert F. Kennedy ...

The FDA approved Liquidia’s treprostinil program for two related kinds of high blood pressure, turning up the heat on rival ...

Plus, news about Lexeo, TreeFrog Therapeutics, Hansa Biopharma, AbbVie, Elpiscience Biopharmaceuticals, Immutep, Hedera Dx, ...

Gilgamesh's GM-2505 shows strong results in Phase 2a depression trial, with 21.6-point symptom reduction after two weeks vs ...

Bio­gen is div­ing in­to the RNAi field with City Ther­a­peu­tics, a biotech led by sev­er­al for­mer Al­ny­lam lead­ers.

Trials for mental health drugs sometimes fail not because the medicine does not work, but because the measure of its effects is unreliable. Brooklyn Health’s technology aims to change that, and share ...

Angelini will pay $50 million upfront and up to $520 million in biobucks to Grin for the ex-North America rights to ...

Prothena abandons birtamimab after Phase 3 amyloidosis trial failure, plans layoffs. Drug previously failed mid-stage trial.

ProteinQure raises $11M Series A led by Heron Rock to advance PQ203, a peptide-drug conjugate for triple-negative breast ...

Protein degrader shop GlycoEra, spun out of vaccines company LimmaTech in 2021, has corralled $130 million in Series B ...